A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
Launched by MODERNATX, INC. · Jul 25, 2023
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing.
- • Body mass index of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the Screening visit.
- • For female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding.
- Key Exclusion Criteria:
- • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius \[°C\]/100.4 degrees Fahrenheit \[°F\]) 72 hours prior to or at the Screening Visit or Day 1.
- • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
- • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
- • Participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams \[mg\]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- • Participant has received any vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
- • Participant has participated in an interventional clinical study within 28 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study.
- • Other inclusion/exclusion criteria may apply.
About Modernatx, Inc.
ModernaTX, Inc. is a pioneering biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Established with a commitment to addressing unmet medical needs, Moderna leverages its proprietary platform to create innovative therapies and vaccines for a variety of diseases, including infectious diseases and cancer. The company gained global recognition for its rapid development of an mRNA-based COVID-19 vaccine, showcasing its agility and expertise in the biopharmaceutical landscape. Through robust clinical trials and a commitment to scientific excellence, ModernaTX aims to redefine the future of medicine and enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southampton, England, United Kingdom
London, , United Kingdom
London, , United Kingdom
Lenexa, Kansas, United States
Tomball, Texas, United States
London, , United Kingdom
London, , United Kingdom
South Jordan, Utah, United States
Newcastle Upon Tyne, England, United Kingdom
Hollywood, Florida, United States
Sugar Land, Texas, United States
Southfield, Michigan, United States
Savannah, Georgia, United States
Lincoln, Nebraska, United States
East Greenwich, Rhode Island, United States
Birmingham, London, United Kingdom
Bradford, London, United Kingdom
Bristol, London, United Kingdom
Cardiff, London, United Kingdom
Salford, London, United Kingdom
Truro, London, United Kingdom
Wrexham, London, United Kingdom
Norwich, Norfolk, United Kingdom
Corby, Northamptonshire, United Kingdom
Edinburgh, , United Kingdom
London, , United Kingdom
North Finchley, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported